HCWB - HCW Biologics shares jump 10% after FDA greenlight for HCW9218 pancreatic cancer study

HCW Biologics (NASDAQ:HCWB) has been cleared by the U.S. FDA to proceed to evaluate its lead drug candidate, HCW9218, in a first-in-human Phase 1b clinical trial in patients with advanced pancreatic cancer. Shares up more than 10% premarket. HCW9218 is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity. In preclinical studies, HCW9218 showed enhanced anti-tumor efficacy of chemotherapy docetaxel and gemcitabine plus nab-paclitaxel against melanoma and pancreatic cancer, respectively, the company said.

For further details see:

HCW Biologics shares jump 10% after FDA greenlight for HCW9218 pancreatic cancer study